



PRESS RELEASE

Contact: Margaret Genest
mgenest@bioarray.us

BIOARRAY Genetics Inc.

For immediate release

BIOARRAY Genetics Inc. announces the launch of a novel oncology gene panel that provides global insight into cancer response to treatments to accelerate drug discovery and development.

Farmington, CT - April 5, 2017: BIOARRAY Genetics Inc. (BIOARRAY), a clinical-stage molecular diagnostics company, announced the launch of a novel oncology gene panel, BA325, a research and development tool that accelerates drug discovery and development for cancer treatments by providing new information on cancer response to treatments. BA325 contains 32 genes that are currently drug treatment targets and provides comprehensive information about oncology drug sensitivity and resistance.

BIOARRAY's BA325 RNA-biomarker panel was derived by querying normal organizational phenotypes. This phenotype-based approach identified genes important to epithelial cell organization in a physiologically relevant context. As a result the selected biomarkers have greater utility in testing tumor samples, because, of the 325 genes identified, 251 are novel and not present in nine other commercially available oncology gene panels. While other oncology biomarker panels are proliferation centric, BIOARRAY's genes bring complementary information with diverse interconnected cell signaling pathways beyond proliferation. "For over a century pathologists have understood that there is a relationship between the microscopic structure of a tumor and clinical outcome. Even today, physicians use a tumor grading system based on the relative preservation of normal tissue and cell structures as a guide for treatment. BA325 provides a rich source of gene expression patterns showing how tumors deviate from their normal state, and provides novel guidance for drug development and rationale for companion diagnostics for new therapies, including immuno-oncology drugs" - said BIOARRAY's CTO Edward C. Goodwin, PhD.

At the 2017 Annual Meeting of the American Association for Cancer Research hosted this week in Washington DC, BIOARRAY presented recent studies describing details of BA325's cell signaling pathways network coverage and technical validation of the assay. "Aligning with the Cancer Moonshot program, we're offering evidence-based predictive diagnostics which will benefit cancer patients by providing actionable information about their treatment options. BA325 brings a new perspective to complement current available information on how drugs work - or don't work. We have a highly skilled, growing team working to accelerate oncology drug discovery and development through industry and clinical partnerships." - said BIOARRAY's CEO and founder Marcia Fournier, PhD.

The new studies come shortly after new funding from private investors in conjunction with Connecticut Innovations, a *quasi-public* venture, and the 2016 election of seasoned executives Pamela Layton as President and Executive Chairman; and Jim LaFrance, Director of the Board of Directors. The company's Advisory Team includes scientists Professor Emeritus Arthur Pardee of Harvard Medical School and Mina Bissell of the Lawrence Berkeley National Laboratory, as well as leaders in the diagnostic industry, including Don Hardison, CEO of Bio-



PRESS RELEASE

Contact: Margaret Genest
mgenest@bioarray.us

Theranostics and Frank Witney, Former CEO of Affymetrix. Most recently, BIOARRAY signed a sponsored research agreement with UCONN Health to perform a final pre-market clinical study on the company's first clinical diagnostic for breast cancer. The company has a growing pipeline with five tests for common chemotherapies as well as immuno-oncology drugs for breast, lung, and colon cancers.

More information about BIOARRAY:

<http://bioarray.us/>